What we are studying
The purpose of this study is to examine the effectiveness (how well the drug works) of a drug called ipilimumab (Yervoy™) either given alone or in combination with an experimental immunotherapy drug for melanoma. We want to see if the combination is better than the ipilimumab given by itself. Ipilimumab at a dose of 3 mg/kg has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic melanoma.
$50 travel reimbursement for study related visits only (if randomized to the experimental drug)